As per the annual meeting notice the options, I guess this KPI...

As per the annual meeting notice the options, I guess this KPI has to be met before this options are exercised and not issued, correct?

For SI,

Vesting for the proposed issue of options will be contingent on achievement of the following milestones, being:
• LTI Commercialisation/Clinical KPIs – 60% (1,395,000 options): commercial and clinical milestones in relation
to the potential launch of remestemcel-L; and
• LTI Financial/Business KPIs – 40% (930,000 options): financial and business development milestones in relation
to remestemcel-L and rexlemestrocel-L platforms.

For Rose,

Vesting for the proposed issue of options will be contingent on achievement of the following milestones, being:
• LTI Regulatory KPIs (600,000 options): milestones related to the regulatory progress of remestemcel-L for
pediatric patients with SR-aGVHD with the United States Food and Drug Administration (FDA), including the
resubmission of its Biologics License Application and its potential approval by the FDA; and
• LTI Clinical KPIs (300,000 options): milestone related to the clinical progress of the Company’s lead products.